Semanteon Capital Management LP Acquires New Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Semanteon Capital Management LP purchased a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 32,864 shares of the medical technology company’s stock, valued at approximately $302,000.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in Alphatec during the fourth quarter valued at $29,000. Nisa Investment Advisors LLC boosted its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares during the last quarter. Newton One Investments LLC bought a new stake in Alphatec during the fourth quarter valued at $50,000. AlphaQuest LLC bought a new stake in Alphatec during the fourth quarter valued at $80,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Alphatec during the fourth quarter valued at $106,000. Institutional investors own 66.35% of the company’s stock.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $9.93 on Friday. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.54. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -7.76 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm’s 50-day simple moving average is $10.96 and its 200 day simple moving average is $8.83.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The business had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares in the company, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 12,691 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now owns 5,857,603 shares of the company’s stock, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 337,321 shares of company stock worth $3,828,060. Insiders own 22.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ATEC. Piper Sandler upped their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Barclays increased their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.